Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multi-Center International, Randomized, Active-Controlled Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

NCT05293665 is registered in ClinicalTrials.gov with Vaxxinity, Inc. as lead sponsor.

NCT NCT05293665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05293665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multi-Center International, Randomized, Active-Controlled Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine
Lead sponsor
Vaxxinity, Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
March 16, 2022
Completion date
September 30, 2023
Enrollment
944 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 vaccines